Liver Cancer Diagnostics Market (By Test Type: Laboratory Tests, Imaging Tests, Endoscopy, Biopsy, Others; By End-use: Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & CRO Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Liver Cancer Diagnostics Market, By Test Type

7.1.  Liver Cancer Diagnostics Market, by Test Type, 2021-2030

7.1.1.    Laboratory Tests

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Imaging Tests

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Endoscopy

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Biopsy

7.1.4.1.        Market Revenue and Forecast (2017-2030)  

Chapter 8.  Global Liver Cancer Diagnostics Market, By End-use

8.1.  Liver Cancer Diagnostics Market, by End-use, 2021-2030

8.1.1.    Hospitals & Diagnostic Laboratories

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Academic & Research Institutes

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Pharmaceutical & CRO Laboratories

8.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Liver Cancer Diagnostics Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Test Type (2017-2030)

9.1.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Test Type (2017-2030)

9.2.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Test Type (2017-2030)

9.3.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Test Type (2017-2030)

9.4.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Test Type (2017-2030)

9.5.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Test Type (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

Chapter 10.  Company Profiles

10.1.              Abbott Laboratories

10.1.1.  Company Overview

10.1.2.  Test Type Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              F. Hoffmann-La Roche Ltd.

10.2.1.  Company Overview

10.2.2.  Test Type Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Qiagen N.V.

10.3.1.  Company Overview

10.3.2.  Test Type Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Thermo Fisher Scientific, Inc.

10.4.1.  Company Overview

10.4.2.  Test Type Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Siemens Healthineers

10.5.1.  Company Overview

10.5.2.  Test Type Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Becton Dickinson & Company

10.6.1.  Company Overview

10.6.2.  Test Type Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Illumina, Inc.

10.7.1.  Company Overview

10.7.2.  Test Type Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Koninklijke Philips N.V.

10.8.1.  Company Overview

10.8.2.  Test Type Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              Epigenomics AG

10.9.1.  Company Overview

10.9.2.  Test Type Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           Fujifilm Medical Systems U.S.A., Inc.

10.10.1.               Company Overview

10.10.2.               Test Type Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms